High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: preliminary results of a prospective single institution study

Bita Kalaghchi, MD1, Ebrahim Esmati, MD2, Reza Ghalehtaki, MD3, Marzieh Gomar, MD3, Ramin Jaberip, PhD2, Sara Gholami, MSc2, Somayeh Babaloui, PhD4, Mansoureh Nabavi, MSc2, Sarvazad Sotoudeh, MD3, Nazhat Khanjani, MD5, Ali Kazemian, MD2, Farnaz Amouzegar-Hashemi, MD2, Mahdi Aghili, MD2, Marzieh Lashkari, MD2

1Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, 2Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, 3Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, 4Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, 5Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Purpose: Skin cancers are the most common human malignancy with increasing incidence. Currently, surgery is standard of care treatment for non-melanoma skin cancers. However, brachytherapy is a growing modality in the management of skin cancers. Therefore, we aimed to assess the outcome of patients with non-melanoma skin cancers treated by high-dose-rate (HDR) brachytherapy with surface mold technique.

Material and methods: In this prospective study, we recruited patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin who were candidates for definitive or adjuvant brachytherapy during 2013-2014. Alginate was used for making the individualized surface molds for each patient. Patients were treated with after-loading radionuclide HDR brachytherapy machine, with a total dose of 30-52 Gy in 10-13 fractions. Participants were followed for 2 years for radiation toxicity, cosmetic results, and local failures.

Results: A total of 60 patients (66.7% male; median age, 71 years) were included, of which 42 (70.0%) underwent definitive radiotherapy. Seventy-five percent of lesions were BCC. The mean total dose was 39.6 ± 5.4 Gy. Of patients in definitive group, 40/42 (95.2%) experienced complete clinical response after 3 months. The recurrence rate was 2/18 (11.11%) and 1/42 (2.38%) in adjuvant and definitive groups, respectively. The percentage of grade 3-4 acute (3-month post-treatment) and late toxicities (2 years post-treatment) was 6.7% and 0%, respectively. The cosmetic results were good/excellent in 96.2% of patients after 2 years of follow-up.

Conclusions: With appropriate patient selection and choosing as lowest dose per fraction as possible, HDR brachytherapy with customized surface molds yields good oncological and cosmetic results for the treatment of localized skin BCC and SCC.

Key words: brachytherapy, mold, skin neoplasms, toxicity.
estimated at 5% [4,5,6]. The Mohs’ micrographic surgery (MMS) is the surgical technique of choice to achieve the oncological cure, preserve function, and restore cosmesis [7]. However, radiotherapy is appropriate in patients in whom surgery may produce esthetic defects, or in those with comorbidities who are unable to undergo an invasive intervention. Additionally, it is indicated as an adjuvant treatment after surgery in cases of close or positive margins. The radiation therapy is as effective as surgical techniques other than MMS.

Various radiotherapy techniques have been developed to treat skin cancer such as superficial orthovoltage X-ray, electron beam, megavoltage photons, low-dose- or high-dose-rate brachytherapy, and the newly emerging electronic brachytherapy [8]. Orthovoltage X-rays, despite being efficient for delivering high doses to skin surface, are not accessible in most radiation therapy centers, particularly in middle-income countries, due to their limited clinical coverage and cost-effectiveness. Electron beam therapy is time-consuming due to individualized beam shaping and has dosimetric challenges in treating small fields [9].

Brachytherapy has been used for the treatment of malignancies since Curie and Becquerel discovered radium, and it was first applied for skin cancer treatment in 1899 [10]. Direct contact therapy was the technique of choice in the first few decades with a 10-year control rate of 73.8% [11]. By the mid-1940s, brachytherapy lost its popularity in the treatment of skin lesions [12], until the introduction of remote afterload machines in the 1960s [13]. One of the techniques used in modern brachytherapy is placing the radioactive sources on the body surface. To do so, custom molds are created from the surface of the lesion’s location. Then, catheters are implanted into the molds for afterloading of the radioactive isotopes [14].

Among the non-surgical treatments of skin cancers, there is a scarcity of data on the efficacy and outcome of high-dose-rate brachytherapy (HDR-BT) with surface molds on Iranian population, where MMS is not widely available. Also, the global experience is growing and needs further works. Accordingly, we aimed to carry out a prospective observational study on the oncological and cosmetic outcomes as well as toxicity profiles of HDR-BT with surface molds on patients with NMSC.

**Material and methods**

**Patient characteristics**

In this prospective study, all patients with pathologically proven NMSC, referring to the Cancer Institute of Imam Khomeini Hospital from September 2013 to August 2014 for definitive or adjuvant treatment with HDR-BT were included. The patients underwent clinical examination with fully exposed skin and imaging studies as indicated to rule out nodal/visceral metastasis. Indications of brachytherapy in these patients were: 1. definitive treatment of T1-2 N0 tumors; 2. adjuvant treatment after surgical excision with a positive margin or residual (microscopic or gross) disease. Patients were excluded from the study if their lesions were thicker than 1 cm, extended to the periosteum or brain parenchyma, or metastasized to the lymphatics or distant viscera. Therefore, thorough explanations were given to the eligible patients on the aims of the study, its protocol, possible complications, and the importance of such survey. An informed written consent was obtained from the subjects willing to participate.

**Treatment customization and planning**

After initial examinations, the physicians had to draw the treatment region of interest (ROI) on the skin surface. The ROI was the visible tumor plus a 1 to 2 cm radial margin. For the adjuvant cases, surgical bed with zero to one cm margin depending on the status of surgical margins formed the ROI. This drawing represented the mold periphery. Alginate was used for creating the mold. After mold formation, a piece of metal wire was placed at the edges. The catheters were implanted in the mold. The number of catheters and their distribution was determined based on the size of the tumor/tumor bed and its location. The catheters were placed with 1 cm-space from each other in a single plane. Plastic tube applicators (French 5) were used for afterloading of radioactive sources. Computed tomography (CT) simulation with 1 mm thickness slices was made for planning with the mold in place. Clinical target volume was drawn in the Flexiplan software version 2.6 (Isodosecontrol BV., Veenendaal, The Netherlands) according to the metal wire visible in images. The depth of the desired CTV was based on imaging findings (simulation CT or pre-treatment magnetic resonance imaging [MRI]). The maximum allowed depth was 10 mm from the skin surface. Paris system dosimetry was used for planning. A radiation oncologist controlled the treatment plan concerning D90 (the dose that 90% of the target volume receives), V100 (the volume receiving 100% of the prescribed dose), and conformity index (>70% was considered acceptable). Flexitron (Elekta) machine was used for afterloading the radionuclide sources (192Ir) to the treatment positions. Figure 1 shows a finalized three-dimensional plan in one of our patients with scalp BCC who underwent adjuvant radiotherapy due to positive surgical margin.

**Follow-up**

Patients were followed for 2 years after treatment. Based on the guidelines of Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [15], acute toxicity (erythema and wet desquamation) was evaluated through examination at day one, 1, and 3 months after the treatment. Similarly, the patients were examined after 6 months, 1 year, and 2 years post-treatment for an incident of late toxicity (atrophy and pigmentation). The patients were also evaluated for response to treatment, cosmetic results, and signs of recurrence. Examination and observations were completed by two radiation oncologists. Suspected recurrences were confirmed by punch biopsy and pathologic review.

**Outcome measures**

The primary outcomes in this study were acute and late complications. The secondary outcomes included response
to treatment, local control, and overall survival and cosmetic results. Overall survival was defined as the fraction of patients who survived after the end of radiotherapy to the end of the first or second year of follow-up. Local control rate was defined as the percentage of patients without persistent/residual lesions or recurrence in the same site one or two years after the treatment. The cosmetic results were assessed by two physicians based on the tool that was developed by authors (Table 1). We defined two cosmetics groups for simplicity and less inter-observer bias.

**Statistical analysis**

The patients were subdivided into two groups including definitive and adjuvant radiotherapy for comparison.

**Table 1.** The tool for the assessment of the cosmetic results by the physician

| Cosmetic assessment group | Items                                      |
|---------------------------|--------------------------------------------|
| Good/excellent (all of the items) | No to mild telangiectasia                   |
|                           | No to mild fibrosis                         |
|                           | No to mild hypo- or hyper-pigmentation      |
| Bad (either of the items)  | Moderate to severe fibrosis                 |
|                           | Skin contracture                            |
|                           | Moderate to severe hypo- or hyper-pigmentation |
χ² test was used to compare the rate of treatment-related toxicity between groups. Kaplan-Meier method was applied for estimation of actuarial survival rate and curves. We used log-rank test to compare survival rates between groups. Actuarial rates of overall survival and local failure were calculated based on the time interval from the last radiotherapy session to the last uneventful follow-up, or all-cause mortality and the date of failure, respectively. SPSS software version 22 (IBM Corp., Chicago, IL, USA) was used for all analyses. The level of significance for all statistical tests was placed at 0.05. Time-event rates were presented with confidence interval 95% (CI 95%).

Results

Patients and tumors characteristics

A total of 60 patients were recruited for the study. Male to female ratio was 40 : 20, and the BCC to SCC ratio was 45 : 15. The median age was 71 years, ranging from 37 to 100 years. The most and least frequent sites of involvement were scalp (33%) and eyelid (3%), respectively. The median tumor size and thickness were 3 cm (range, 0.5-12) and 0.5 cm (range, 0.1-1), respectively. The intention of brachytherapy was definitive in 42 patients (70%) and adjuvant in the remaining. As presented in Table 2, there was no significant difference between the two groups of definitive and adjuvant treatment in terms of gender, age, the situation of the tumor, or pathology of lesion.

Dose and planning characteristics

The characteristics of prescribed total dose, dose per fractions and D90 and V100 are presented in Table 2. The median dose/fraction was 3 Gy in the definitive, and 4 Gy in the adjuvant setting. The range of total physical dose was between 30 and 52 Gy. This dose was prescribed in a minimum of 10 and a maximum of 13 fractions. The median EQD2 was 42.2 Gy (range, 33-61), 42.2 Gy, and 54.4 Gy in all, definitive, and adjuvant groups, respectively. The median V100 was 14.5 ml (range, 2.6-152.8) and 38.5 ml (range, 4.9-129.5) in the definitive and adjuvant settings, respectively.

As evident in Table 2, no significant difference was observed between the two groups of definitive and adjuvant in quantitative treatment parameters measured, except for total EQD2 dose that was higher in the adjuvant setting.

Table 2. General characteristics of the patients and the treatment parameters

| Qualitative variables | Total frequency (%) | Group | p value |
|-----------------------|---------------------|-------|---------|
|                       | Definitive frequency (%) | Adjuvant frequency (%) |
| Gender                |                      |       |         |
| Female                | 20 (33.3)            | 14 (33.3) | 6 (33.3) | 1.000 |
| Male                  | 40 (66.7)            | 28 (66.7) | 12 (66.7) |
| Age group             |                      |       |         |
| ≤ 70                  | 29 (48.3)            | 20 (47.6) | 9 (50.0) | 0.866 |
| > 70                  | 31 (51.7)            | 22 (52.4) | 9 (50.0) |
| Location              |                      |       |         |
| Face                  | 19 (31.7)            | 11 (26.2) | 8 (44.4) | 0.132 |
| Scalp                 | 20 (33.3)            | 13 (31.0) | 7 (38.9) |
| Nose                  | 15 (25.0)            | 14 (33.3) | 1 (5.6) |
| Ear                   | 4 (6.7)              | 2 (4.8) | 2 (11.1) |
| Eyelid                | 2 (3.3)              | 2 (4.8) | 0 (0.0) |
| Pathology             |                      |       |         |
| BCC                   | 45 (75.0)            | 33 (78.6) | 12 (66.7) | 0.347 |
| SCC                   | 15 (25.0)            | 9 (21.4) | 6 (33.3) |
| Quantitative variables | Total mean (std. dev.) | Definitive mean (std. dev.) | Adjuvant mean (std. dev.) | p value |
| Duration (days)       | 15.8 (4.2)           | 16.0 (4.1) | 15.4 (4.3) | 0.646 |
| Total dose (Gy)       | 39.6 (5.4)           | 38.8 (5.4) | 41.5 (4.9) | 0.064 |
| Total dose EQD2 (Gy)  | 44.9 (7.7)           | 42.9 (6.7) | 49.6 (8.2) | 0.002 |
| Number of fractions   | 11 (1.4)             | 11 (1) | 11 (1) | 0.728 |
| D90 (Gy)              | 3.6 (0.6)            | 3.5 (0.6) | 3.8 (0.7) | 0.228 |
| V100 (cm³)            | 34.9 (35.5)          | 29.7 (34.8) | 47.1 (35.1) | 0.088 |

BCC – basal cell carcinoma, SCC – squamous cell carcinoma, EQD2 (Gy) – equivalent dose at 2 Gy, D90 (Gy) – the minimum dose received by 90% of the target volume, V100 (cm³) – the percentage of the target volume receiving 100% of the prescribed dose or more.
Post-treatment complications

Acute toxicity

One day after treatment, 26 patients (43.3%) had grade 1-2, and 31 (51.7%) experienced grade 3-4 acute toxicity. Although the rate of grade 3-4 toxicities among the patients who underwent brachytherapy as definitive treatment was higher than the adjuvant group, the differences were not statistically significant. One month after treatment, 25% of patients were found to have grade 3-4 toxicities. By the end of third month, this figure decreased to 6.7%. Similarly, the rates of toxicities were higher in the definitive group, although the differences were non-significant (Table 2).

Late toxicity

Patients were assessed for the late toxicities at 6 months, one year, and two years post-treatment. More than half of patients (50.8%) had signs of late grade 1-2 toxicity at 6 months follow-up, which decreased to 43.1% after 1 year. Nevertheless, only one patient showed signs of grade 3-4 toxicity, which was resolved by the 2nd year of follow-up. Thus, the rate of late grade 3-4 toxicity was 1.6%, 1.6%, and 0% at 6th month, 1st year, and 2nd year of follow-up, respectively. Definitive and adjuvant groups were not significantly different from each other considering the rate and grade of late toxicities (Table 3).

Clinical outcomes

Cosmetic results

By the end of the first year, out of 58 live patients, 55 (94.8%) were found to have a good/excellent cosmetic outcome. Accordingly, this rate was found to be 92.7% in the definitive group and 100% in the adjuvant group. By the end of 2nd year of follow-up, the percentage of good/excellent cosmetic outcome increased to 96.2% in 52 individuals, 94.4% in definitive, and 100% in adjuvant group (p = 0.961).

Response to treatment

Among patients in the definitive group after 1 month, the disease was stable in only 1 patient (2.4%), two pa-

| Table 3. Acute and chronic toxicities and cosmetic results of the treatment |
|-------------------------------------------------------------|
| **Total frequency (%)** | **Group** | **p value** | **Definitive frequency (%)** | **Adjuvant frequency (%)** |
|------------------------|----------|-------------|-------------------------------|-----------------------------|
| **Acute toxicity**     | One day after treatment | No toxicity | 3 (5.0) | 1 (2.4) | 2 (11.1) | 0.358 |
|                        |                      | Grade 1-2   | 26 (43.3) | 19 (45.2) | 7 (38.9) |          |
|                        |                      | Grade 3-4   | 31 (51.7) | 22 (52.4) | 9 (50.0) |          |
| 1 month after treatment| No toxicity         | 23 (38.3)   | 17 (40.5) | 6 (33.3) |          | 0.869 |
|                        | Grade 1-2           | 22 (36.7)   | 15 (35.7) | 7 (38.9) |          |          |
|                        | Grade 3-4           | 15 (25.0)   | 10 (23.8) | 5 (27.8) |          |          |
| 3 months after treatment| No toxicity       | 44 (73.3)   | 30 (71.4) | 14 (77.8) |          | 0.397 |
|                        | Grade 1-2           | 12 (20.0)   | 10 (23.8) | 2 (11.1) |          |          |
|                        | Grade 3-4           | 4 (6.7)     | 2 (4.8)   | 2 (11.1) |          |          |
| **Late toxicity**      | 6 months after treatment | No toxicity | 29 (49.2) | 18 (43.9) | 11 (61.1) | 0.417 |
|                        | Grade 1-2           | 29 (49.2)   | 22 (53.7) | 7 (38.9) |          |          |
|                        | Grade 3-4           | 1 (1.7)     | 1 (2.4)   | 0 (0.0)  |          |          |
| 1 year after treatment | No toxicity         | 33 (56.9)   | 21 (51.2) | 12 (70.6) |          | 0.361 |
|                        | Grade 1-2           | 24 (41.4)   | 19 (46.3) | 5 (29.4) |          |          |
|                        | Grade 3-4           | 1 (1.7)     | 1 (2.4)   | 0 (0.0)  |          |          |
| 2 years after treatment| No toxicity         | 27 (51.9)   | 16 (44.4) | 11 (68.8) |          | 0.138 |
|                        | Grade 1-2           | 25 (48.1)   | 20 (55.6) | 5 (31.3) |          |          |
|                        | Grade 3-4           | 0 (0.0)     | 0 (0.0)   | 0 (0.0)  |          |          |
| **Cosmetic results**   | After 1 year        | Bad         | 3 (5.2)   | 3 (7.3)   | 0 (0.0)  | 0.548 |
|                        | Good                | 55 (94.8)   | 38 (72.7) | 17 (100.0) |          |          |
|                        | After 2 years       | Bad         | 2 (3.8)   | 2 (5.6)   | 0 (0.0)  | 0.336 |
|                        | Good                | 50 (96.2)   | 34 (94.4) | 16 (100.0) |          |          |
Table 4. Effect of dosimetric parameters on outcomes

| Setting      | Dosimetric parameter | Grade 2-4 acute toxicity | Grade 2-4 late toxicity | Bad cosmetic results | Local failure |
|--------------|----------------------|--------------------------|-------------------------|----------------------|---------------|
| Definitive   | Dose/fraction        | ≤ 3 Gy 18 (85.7)         | 1 (4.8)                 | 1 (4.8)              | 0 (0)         |
|              |                      | > 3 Gy 19 (90.5)         | 5 (25)                  | 2 (10)               | 2 (9.5)       |
|              | p value              |                          |                         | 0.99                 | 0.09          |
|              |                      | Total dose EQD2          | ≤ 42.25 Gy 27 (84.4)    | 5 (15.6)             | 3 (9.4)       |
|              |                      | > 42.25 Gy 10 (100)      | 1 (11.1)                | 0 (0)                | 0 (0)         |
|              | p value              |                          |                         | 0.31                 | 0.99          |
|              |                      | V100                     | ≤ 15 17 (81)            | 0 (0)                | 0 (0)         |
|              |                      | > 15 20 (95.2)           | 6 (30)                  | 3 (15)               | 2 (9.7)       |
|              | p value              |                          |                         | 0.34                 | 0.01          |
| Adjuvant     | Dose/fraction        | ≤ 3.5 Gy 6 (66.7)        | 1 (10)                  | 0 (0)                | 0 (0)         |
|              |                      | > 3.5 Gy 6 (75)          | 1 (12.5)                | 0 (0)                | 2 (25)        |
|              | p value              |                          |                         | 0.99                 | 0.99          |
|              |                      | Total dose EQD2          | ≤ 46.67 Gy 5 (55.6)     | 2 (22.2)             | 0 (0)         |
|              |                      | > 46.67 Gy 7 (87.5)      | 0 (0)                   | 0 (0)                | 2 (22.2)      |
|              | p value              |                          |                         | 0.29                 | 0.47          |
|              |                      | V100                     | ≤ 38.5 4 (50)           | 0 (0)                | 0 (0)         |
|              |                      | > 38.5 8 (88.9)          | 2 (22.2)                | 0 (0)                | 2 (22.2)      |
|              | p value              |                          |                         | 0.13                 | 0.47          |

EQD2 (Gy) – equivalent dose at 2 Gy, $V_{100}$ (cm³) – the percentage of the target volume receiving 100% of the prescribed dose or more.

Fig. 2. The Kaplan-Meyer graph for actuarial local control.

The blue and green lines represent definitive and adjuvant treatments, respectively.

Local control

The lesions recurred in 2/18 patients (11.1%) who underwent adjuvant treatment. The recurrences were treated by surgical excision. Among patients undergoing definitive therapy, 2/42 (4.7%) experienced local failure after 3 months. In both groups, no other recurrences occurred until the end of 2 years follow-up. As depicted in Figure 2, the 2-year actuarial local control rate was calculated to be 95% (CI 95%: 89-100) in the definitive group, and 88% (CI 95%: 74-100) in the adjuvant group.

Overall survival

Median follow-up time was 2 years (range, 3-24 months). During this time, six persons died (1 by 6 months, 2 by the first year). Only one of these patients who underwent definitive HDR-BT for scalp lesion deceased because of their disease (after recurrence), and the other five died due to other causes than the malignancy. The 2-year overall
survival (OS) rate was 87%, 86%, and 89% in total, definitive, and adjuvant groups, respectively.

Effect of dosimetric parameters on outcomes

As shown in Table 4 and 5, among patients undergoing definitive brachytherapy, higher dose per fraction and V100 were associated with a trend toward a higher frequency of grade 2 or greater late toxicities, with p values less than 0.1 and 0.01, respectively. After multivariate analysis, only V100 > 15 ml was independent predictor of late toxicity in definitive cases. Otherwise, in both univariate and multivariate analyses, there were no significant associations among the parameters, and late toxicity, acute toxicity, cosmetic results, and local failure in either definitive or adjuvant settings.

Discussion

The outcome and cosmetic results of HDR-BT along with its associated acute and late toxicity were assessed in this prospective study conducted on patients with NMSC. The age distribution of our patients was the same in the adjuvant and definitive groups. One could presume that patients in the adjuvant groups should be significantly younger. This presumption roots in the potential risk of radiation-induced second neoplasms. The reason is that the standard Mohs’s surgery is not routinely carried out in most parts of Iran. At present, extensive surgical excisions to achieve wide negative margins are not associated with good treatment outcomes and acceptable toxicity. Interestingly, we found that post-treatment/fraction over 3 Gy was associated with higher late toxicity in the definitive setting. Thus, this is a possible explanation for our high toxicity rates. Also, the mean depth of the lesions studied was more elevated than similar investigations. When treating deep-seated tumors, the superficial skin placed in D100 or D150 and consequently, receives higher doses than the most in-depth segment. This non-uniformity (over 3%) could be another explanation for our higher toxicities compared to the literature [16].

In similar studies reporting the results of HDR-BT treatment with surface molds, the range of local control varied between 87% to 100% [17,18,19,20]. Considering CI 95%, our 2-year local control was in agreement with other studies. Although, several factors have been proposed for differences observed in local control rates; these include tumor size (small vs. large), location (plain vs. curved surfaces), treatment margin, and histology (BCC vs. SCC). In our study, the majority of recurrent cases were large lesions on the scalp with BCC histology. Our small sample size limited the potential to compare the effect of these factors on local control. Nevertheless, there was no statistically significant difference between definitive and adjuvant treatment groups.

Our cosmetic results with HDR-BT were quite promising, with more than 95% of cases showing good/excellent results after two years of follow-up. Other studies using HDR-BT or electronic brachytherapy achieved similar results [8,21,22].

HDR-BT was quite tolerable by our patients, with meager rates of severe acute and late toxicities. Theoretically, some investigators believed that large fraction size used with HDR-BT might be associated with higher late toxicity [19,20,21]. Although several other investigations counteracted this belief, our study suggested that the lower dose/fraction, the better late toxicity profile. Overall, the results of all the available literature on this subject, including the present study indicates that HDR-BT is associated with good treatment outcomes and acceptable acute and late complications. Therefore, this modality could be considered as a mainstay treatment for NMSC located on the nose, eyelid, ear, and any other region where surgical excision might be difficult, or the required anesthesia harbors high-risk for patient life. This is particularly the issue in the elderly and frail patients who

### Table 5. Characteristics of patients with local failures

| Setting | Time of evaluation | Physical Dose/no of fractions | Dose/fraction | EQD2 | V100 (ml) | Histologic type | Location | Age | Gender |
|---------|--------------------|------------------------------|---------------|-------|-----------|----------------|----------|-----|--------|
| 1st Patient | Definitive | 3 months | 45/10 | 4.5 | 42.25 | 152.8 | BCC | Scalp | 77 | Male |
| 2nd Patient | Definitive | 3 months | 48/12 | 4 | 39.38 | 64 | BCC | Scalp | 70 | Male |
| 3rd Patient | Adjuvant | 3 months | 45/10 | 4.5 | 54.38 | 53.6 | BCC | Scalp | 60 | Male |
| 4th Patient | Adjuvant | 3 months | 45/10 | 4.5 | 54.38 | 53.6 | BCC | Scalp | 60 | Female |

EQD2 (Gy) – equivalent dose at 2 Gy, V100 (cm³) – the percentage of the target volume receiving 100% of the prescribed dose or more, BCC – basal cell carcinoma.
share the most substantial contribution to the prevalence of skin cancers [23].

Conclusions

As long as the dose/fraction is kept below 3 Gy/fraction, HDR-BT is an attractive modality to manage skin cancers in the head and neck region with acceptable toxicity and promising cosmetic results. Longer follow-up is needed to establish the long-term local control rates confidently.

Acknowledgments

We would like to appreciate the staff of brachytherapy ward Mrs. Shaahnazari, Mrs. Machinfroosh, and Mrs. Mahdavi for their valuable co-operation in the treatment of our patients and providing the information we needed for this publication.

Disclosure

The authors report no conflict of interest.

References

1. Alam M, Nanda S, Mittal BB et al. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Amer Acad Dermatol 2011; 65: 377-888.
2. Razi S, Rafiemanesch H, Ghoncheh M i wsp. Changing Trends of Types of Skin Cancer in Iran. Asian Pac J Cancer Prev 2015; 16: 4955-4958.
3. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003; 149: 1200-1206.
4. Macfarlane L, Waters A, Evans A et al. Seven years’ experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards. Clin Exp Dermatol 2013; 38: 262-269.
5. Caresana G, Giardini R. Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol 2010; 24: 1395-1399.
6. Chen MM, Torres JS, Stuart SE et al. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol 2011; 147: 540-546.
7. Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002; 3: 193-203.
8. Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy 2013; 12: 134-140.
9. Ouhib Z, Kasper M, Perez Calatayud J et al. Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report. Brachytherapy 2015; 14: 840-858.
10. Hansen PB, Jensen MS. Late results following radiotherapy of skin cancer. Acta Radiol Ther Phys Biol 1968; 7: 307-319.
11. Fürst C, Lundell M, Holm LE. Radiation therapy of hemangiomas, 1909-1959. A cohort based on 50 years of clinical practice at Radiumhemmet, Stockholm. Acta Oncol 1987; 26: 33-36.
12. Moss WT, Brand WN, Battifora H. Radiation oncology: rationale, technique, results. C.V. Mosby Co., St. Louis 1973.
13. Gunderson LL, Tepper JE, Bogart JA. Clinical Radiation Oncology. Elsevier Health Sciences, 2015.
14. Devlin PM. Brachytherapy: applications and techniques. Springer Publishing Company, 2015.
15. Cox JD, Setz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
16. Skowronek J. Brachytherapy in the treatment of skin cancer: an overview. Postep Derm Alergor 2015; 32: 362-367.
17. Guix B, Finestres F, Tello JI et al. Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys 2000; 47: 95-102.
18. Montero A, Hernanz R, Capuz AB et al. High-dose-rate (HDR) brachytherapy with custom-made moulds for the treatment of non-melanoma skin cancer. Clin Transl Oncol 2009; 11: 760-764.
19. Maroñas M, Guinot JL, Arribas L et al. Treatment of facial cutaneous carcinoma with high-dose rate contact brachytherapy with customized molds. Brachytherapy 2011; 10: 221-227.
20. Haseltine JM, Parker M, Wernicke AG et al. Clinical comparison of brachytherapy versus hypofractionated external beam radiation versus standard fractionation external beam radiation for non-melanomatous skin cancers. J Contemp Brachytherapy 2016; 8: 191-196.
21. Paravati AJ, Hawkins PG, Martin AN et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol 2015; 5: e659-e664.
22. Delishaj D, Laliscia C, Manfredi B et al. Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valenctia applicator in elderly patients: a retrospective case series. J Contemp Brachytherapy 2015; 7: 437-444.
23. Lancellotta V, Lupattelli M, Zucchetti C et al. HDR Brachytherapy for Basal Cell Carcinoma. J Nucl Med Radiat Ther 2015; 6: 2.